TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02534636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2a recombinant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00003454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Stage IV Breast Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT01361763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: 110 mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiplatelets
Description: 100mg once a day
Study: NCT01360645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712 + ADT
Description: Tablet, Oral, 2 mg OPC-34712 and FDA Approved Antidepressant Therapy (ADT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo + ADT
Description: Placebo + FDA Approved Antidepressant (ADT)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + ADT
Description: Placebo + FDA Approved Antidepressant (ADT)
Study: NCT01324557

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CSII and MDI
Description: The aims of this study are to assess the potential efficacy and safety of insulin pump(MiniMed Paradigm® REAL-Time Revel™ Insulin Pump) to improve glycemic control in conjunction with continuous glucose monitoring (CGMS) for diabetic CAPD Patients.

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: CSII and MDI
Description: The aims of this study are to assess the potential efficacy and safety of insulin pump(MiniMed Paradigm® REAL-Time Revel™ Insulin Pump) to improve glycemic control in conjunction with continuous glucose monitoring (CGMS) for diabetic CAPD Patients.
Study: NCT01390792

Intervention type: DRUG
Intervention: Zanamivir hydrate
Study: NCT00713219

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT, cetuximab, docetaxel
Description: IMRT will be administered in once daily fractions (2 Gy/day, Monday through Friday) over approximately 7 weeks to a goal of approximately 70 Gy. The chemotherapy regimen will begin with a loading dose of intravenous cetuximab (400 mg/m2) one week prior to the initiation of radiation therapy, followed by weekly administration of intravenous docetaxel (15 mg/m2) and intravenous cetuximab (250 mg/m2) for approximately 7 weeks concurrently with radiation. Patients will be evaluated weekly prior to their chemotherapy. All patients will be evaluated on an intention-to-treat basis.
Study: NCT01769755

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDA001
Description: Cohort 1 Dose Level 1: ¼ unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart.~Cohort 2 Dose Level 2: ½ unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart.~Cohort 3 Dose Level 3: 1 unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Controlled Placebo
Description: Cohort 1 Dose Level 1: ¼ unit vehicle controlled placebo infused a total of 5 times 2 weeks apart.~Cohort 2 Dose Level 2: ½ unit vehicle controlled placebo infused a total of 5 times 2 weeks apart.~Cohort 3 Dose Level 3: 1 unit vehicle controlled placebo infused a total of 5 times 2 weeks apart.
Study: NCT03163654

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery 1
Description: Following local anaesthesia (Articaine hydrochloride 4% with 1:200,000 epinephrine injection) administration, sulcular incisions were made in the recession's areas of teeth without damaging interdental papilla. Mucoperiosteal (MP) dissections were made using the periostal elevator creating the deep pouch beyond the mucogingival junction so that the (MP) flap could be moved coronally without tension. Porcine-derived acellular dermal collagen matrix (PADM) was positioned at the level of a cemento-enamel junction (CEJ) and skin tight for teeth to avoid forming a blood clot. Separate single sutures per tooth with 5-0 resorbable suture were used to stabilise graft. The tunnel flap was positioned coronally above the CEJ to completely cover the graft and sutured with non-resorbable polypropylene suture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery 2
Description: Following local anaesthesia (Articaine hydrochloride 4% with 1:200,000 epinephrine injection) administration, sulcular incisions were made in the recession's areas of teeth without damaging interdental papilla. Mucoperiosteal (MP) dissections were made using the periostal elevator creating the deep pouch beyond the mucogingival junction so that the (MP) flap could be moved coronally without tension. Connective tissue graft was positioned at the level of a cemento-enamel junction (CEJ) and skin tight for teeth to avoid forming a blood clot. Separate single sutures per tooth with 5-0 resorbable suture were used to stabilise graft. The tunnel flap was positioned coronally above the CEJ to completely cover the graft and sutured with non-resorbable polypropylene suture.
Study: NCT03909958

Intervention type: OTHER
Group type: OTHER
Intervention: Electroacupuncture+Routine rehabilitation training Group
Description: Electroacupuncture： Major acupoints: Jiaji points. With urinary and stool dysfunction:+Shenshu (BL23) ,Huiyang(BL35).~Localization:Jiaji points of the upper 1 and the lower 1 segment of the Spinal cord injury plane, a total of 4 points.~Operation: Insert Jiaji points By using Hwato-brand disposable acupuncture needles(0.30mm\*50mm), with 0.5 inch from the median line and a depth of 50 to 60mm with perpendicular insertion.Then, participants will receive electroacupuncture treatment by connecting Han's pain irritant instrument (HANS100A) for 30min with the stimulation frequency of 2 /100 Hz and intensity of 1-2mA. Once a day, 5 days a week and rest 2 days, a week is one course and the duration need 12 courses.~Routine rehabilitation training:~Same as Routine rehabilitation training Group.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Routine rehabilitation training Group
Description: Routine rehabilitation training:~Participants with good spinal stability will receive sitting training as early as possible, and will carry out standing training if participants had no adverse reactions (postural hypotension, etc.) after sitting training. Muscle strength training will be performed in recovery phase, and functional movement training will be selected according to participants' conditions. Functional movement training and transfer training will be performed for 20min each time and once a day;Standing and walking training, 2 times a day, 30min each time.
Study: NCT03973983

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transgluteal pudendal nerve injection (TG-PNI)
Description: Ultrasound-guided transgluteal pudendal nerve local anesthetic injections

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Finger-guided transvaginal pudendal nerve injection (TV-PNI)
Description: Finger-guided transvaginal pudendal nerve local anesthetic injections
Study: NCT00324168

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: moxifloxacin 0.5% every one hour for 48 hours while awake and then every 2 hours until re-epithelialization

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antibiotics
Description: moxifloxacin 0.5% every one hour for 48 hours while awake and then every 2 hours until re-epithelialization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical corticosteroid
Description: prednisolone phosphate 1% with preservative four times a day for 1 week, then twice a day for 1 week, and finally once a day for 1 week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl and preservative (same as in steroid) four times a day for 1 week, then twice a day for 1 week, and finally once a day for 1 week
Study: NCT02359981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyBehavior
Description: The intervention automatically provides personalized suggestions based on users behavior and user context. Suggestions relates to users life and how often they have done them in the past. Since the suggestions relate to users' lives, they are easy to follow.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Generic suggestions
Description: A nutritionist and an exercise trainer jointly created 45 food and exercise suggestions based on guidelines posted by the NIH. These suggestions ask users to walk for 30 minutes or eat healthier foods. These suggestions however doesn't personalize to users daily behavior into account.
Study: NCT03929887

Intervention type: OTHER
Intervention: Kidney Biopsy
Description: Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core and various patient-derived samples.
Study: NCT00707798

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK2189242A
Description: Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2. Six different formulations of this vaccine will be tested

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK2189242A
Description: Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2. Six different formulations of this vaccine will be tested

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK2189242A
Description: Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2. Six different formulations of this vaccine will be tested

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK2189242A
Description: Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2. Six different formulations of this vaccine will be tested

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK2189242A
Description: Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2. Six different formulations of this vaccine will be tested

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK2189242A
Description: Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2. Six different formulations of this vaccine will be tested

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumo 23™
Description: One dose of 0.5 ml will be administered intramuscularly at Month 0, and a placebo dose to keep the blinding at Month 2
Study: NCT01451645

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine (Colcrys®)
Description: daily 0.6 mg colchicine dosing for 16 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: daily placebo dosing for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: allopurinol
Description: background therapy

Intervention type: DRUG
Group type: OTHER
Intervention: allopurinol
Description: background therapy
Study: NCT01692678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Type=exact number, unit=mg/m2, number=1.5, 1.2 or 1.0, form=solution, route=intravenous infusion. Trabectedin will be administered on Day 1 of each 21-day treatment cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: Type=exact number, unit=g/m2, number=1, form=solution, route=intravenous infusion. Dacarbazine will be administered on Day 1 of each 21-day treatment cycle.
Study: NCT01958645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI8111
Description: MEDI8111 lyophilisate for solution for infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for MEDI8111 saline solution for infusion
Study: NCT04244565

Intervention type: BEHAVIORAL
Intervention: Self-directed model of clinical learning for nurses
Description: the instructors play a facilitating role while, learners actively participate in identifying their own learning needs, learning goals, allocating resources \& decide whether learning method can be used, and engaging in self-reflection \& evaluation.
Study: NCT01130571

Intervention type: PROCEDURE
Intervention: Xenografts and cell cultures
Study: NCT02838173

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: serratus plane bloc : Ropivacaine 2mg/ml (0,3ml/kg)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tissue infiltration : Ropivacaine 2mg/ml (0,3ml/kg)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: serratus plane bloc : placebo

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tissue infiltration : placebo
Study: NCT01225562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg
Description: Oral dose twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg
Description: Oral dose twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ticagrelor Placebo
Description: Oral dose twice a day
Study: NCT02705898

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LPA+Fitbit

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HEC
Study: NCT04408807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speculum-free (SpF) fundoscopy
Description: Indirect ophthalmoscopy without the use of eyelid speculum and scleral indentation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Speculum (Sp) fundoscopy
Description: Indirect ophthalmoscopy with the use of eyelid speculum and scleral indentation
Study: NCT00805896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Songyou
Description: 4g/pack

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 4g/pack
Study: NCT01645267

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite
Description: Use of artifical bonegraft material
Study: NCT00364182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Coagulation Factor IX (BeneFIX)
Description: 100 IU/kg once weekly then crossover to 50 IU/kg twice weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Coagulation Factor IX (BeneFIX)
Description: 50 IU/kg twice weekly then crossover to 100 IU/kg once weekly
Study: NCT02431416

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropin releasing hormone (GnRH)
Description: Gonadotropin releasing hormone GnRH (Relefact LHRH) iv injection, single dose, 100 micrograms/square meter body surface, maximum dose: 100 microgram.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: Sodium chlorid 9 mg/mL will be given as a single iv injection with the same volume as the volume used for the active substance injection.
Study: NCT04106622

Intervention type: PROCEDURE
Intervention: electrophysiological study
Description: To assess whether the AP is of high risk or not, for all patients the AERP of the AP will be determined by one of the following ways:~The cycle length at which abrupt and complete loss of pre-excitation occurs during exercise test. If this didn't happen, the patient will be subjected to invasive electrophysiologic study..~The Antegrade refractory period of the AP is measured during EPS as the shortest cycle length with one-to-one conduction over the AP by incremental atrial stimulation after which the QRS becomes narrow or no conduction occurs due to block of the impulse in the AP.~The shortest pre-excited R-R interval during spontaneous or induced AF.
Study: NCT00899093

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00147550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0325901
Description: Administered orally either once or twice a day; several dosing schedules evaluated; current dosing schedule is 5 days on-drug, 2-days off drug for 3 weeks in a 28-day cycle. Doses evaluated ranged from 1 mg once a day to 30 mg twice daily.
Study: NCT02141477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine
Description: Phase I and Phase II Omacetaxine Dose: 1.25 mg/m2 subcutaneously every 12 hours on Days 1 - 3 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Phase I Starting Decitabine Dose: 20 mg/m2 by vein on Days 1 - 5 of a 28 day cycle.~Phase II Starting Decitabine Dose: Maximum tolerated dose from Phase I.
Study: NCT02205489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab GZ402673
Description: Pharmaceutical form:concentration for solution Route of administration: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetirizine
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranitidine
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Pharmaceutical form:solution Route of administration: intravenous
Study: NCT04624425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Segmental breathing exercises
Description: Segmental breathing exercises along with the Conventional Treatment of buteyko breathing exercises for two weeks of duration. Segmental breathing exercises include 18-20 breaths in one session (6 breaths/min) with rest interval after every 6 breaths.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Buteyko breathing exercises
Description: Buteyko exercises for two weeks of duration. Treatment session will be last for 10-15minutes.
Study: NCT04635865

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D-printed patient-specific plate
Description: We adopt an in-house approach for designing by surgeons. All patient-specific devices are designed in 3-matic 13.0 (Materialise). Both cutting and transferring guides are then additively manufactured by Fused Deposition Manufacturing (FDM) using ULTEM 1010, or by Stereolithography using MED610 resin (Stratasys Ltd, Eden Prairie, MN, USA). Both ULTEM 1010 and MED610 are FDA cleared biocompatible materials applicable to high-temperature autoclaving.~Patient-specific surgical plates are designed by delineating a plate path on bone surface, then followed by the placement of screw holes. Surgical plates are generated by the built-in command in 3-matic. After that, surgical plates are fabricated by SLM using grade 2 titanium powder.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional commercial reconstruction plate
Description: Bone segments will be stabilized using commercial titanium surgical plates (DePuy Synthes, United States), which are bent manually before fastening the screws.\[
Study: NCT02979210

Intervention type: OTHER
Group type: OTHER
Intervention: Artificial Fecal Insult
Description: protease/bile acid cocktail 200 microliters (1500 µg/ml trypsin/chymotrypsin protease mixture, 6.5 mg/ml cholic acid sodium, 6.2 mg/ml deoxycholic acid sodium, and 3.1 mg/ml chenodeoxycholic acid sodium in phosphate buffered saline

Intervention type: OTHER
Group type: OTHER
Intervention: Phosphate Buffered Saline
Description: 200 microliters of phosphate buffered saline
Study: NCT02342132

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive bipap ventilator
Description: The non-invasive bipap ventilator will be used in the following respiratory treatment: bipap assisted inspiratory breaths (BAIB). The patient will be encouraged to take deep breaths at least 1.5 times greater than resting tidal volume. The pressure assistance provided by the bipap starts at 10cm H2O. Patients already on bipap will use their home settings. Starting pressure is then increased as necessary to meet the maximal inspiratory goal volume in steps of 2 up to a maximum 20cm H2O. Once the ideal pressure of support levels are established, the child will perform 3 cycles of 5 deep breaths. After each cycle the patient will pause and perform huffing and assisted coughing. The patient will be suctioned as necessary.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical insufflator-exsufflator
Description: A commercial mechanical insufflator-exsufflator will be used in the following treatment: Mechanical insufflation-exsufflation (MI-E). The pressure will be administered by a face mask. The optimal pressure for the test will start at 10 cm H2O and will in crease in steps of 5 to a maximum of 25 cm H2O. The insufflation phase will take 3 seconds followed by a 2 second exsufflation phase. Three cycles of treatment will be used. Between each cycle the subject will pause and perform huffing and assisted coughing. The patient will be suctioned as necessary.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency percussive oscillator
Description: A commercial high frequency percussive oscillator will be used in the following treatment: combined oscillation and nebulisation. Pressures will be delivered by a face mask. At higher oscillation frequencies it is usually necessary to support the cheeks. Pressure will be gradually be increased to accustom the child to a maximum of 25cm H2O. This standard maximal pressure will ideally be used for every child. A treatment cycle will consist of 3 minutes at a frequency of 2 Hz and pressure of 15cm H2O followed by 3 minutes of 4 Hz at 20cm H2O, then 3 minutes of 5 Hz at 25cm H2O. Throughout each cycle, the patient will receive nebulized saline through the machine. After each cycle the patient will pause and perform huffing and assisted coughing. The patient will be suctioned as necessary.
Study: NCT02452762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04070482

Intervention type: OTHER
Intervention: Tenofovir exposure in utero and during breastfeeding
Description: Exposed in utero and during breastfeeding to Tenofovir-containing antiretroviral drugs
Study: NCT02530931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: diffusion of gadolinium for a population with Meniere's disease in order to develop an imaging disease screening test